XML 24 R12.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Segment Reporting | 12 Months Ended
--- | ---
Nov. 30, 2017
Segment Reporting [Abstract] |
Segment Reporting | Note 6 – Segment Reporting During the third quarter of fiscal 2015, the Company purchased certain assets and assumed certain liabilities and contracts that CytoMedical used in the operation of its cord blood business (See Note 2). The Company evaluated and determined that this acquisition qualifies as a separate segment. The Company is organized in two reportable segments:
| 1. | The cellular processing and cryogenic storage of umbilical cord blood and cord tissue stem cells for family use. Revenue is generated from the initial processing and testing fees and the annual storage fees charged each year for storage (the “Umbilical cord blood and cord tissue stem cell service”).
| 2. | The manufacture of PrepaCyte CB units, the processing technology used to process umbilical cord blood stem cells. Revenue is generated from the sales of the PrepaCyte CB units (the “PrepaCyte CB”).
The following table shows, by segment: net revenue, cost of sales, operating profit, depreciation and amortization, interest expense, income tax (expense) benefit, other comprehensive loss, and assets for the years ended November 30, 2017 and 2016:
|  | For the years ended November 30, |
|  | 2017 |  |  | 2016 |
Net revenue: |  |  |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 24,942,089 |  |  | $ | 22,777,919 |
PrepaCyte CB |  |  | 442,190 |  |  |  | 350,128 |
Total net revenue |  | $ | 25,384,279 |  |  | $ | 23,128,047 |
Cost of sales: |  |  |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 6,257,628 |  |  | $ | 5,446,126 |
PrepaCyte CB |  |  | 466,763 |  |  |  | 328,674 |
Total cost of sales |  | $ | 6,724,391 |  |  | $ | 5,774,800 |
Operating profit: |  |  |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 5,067,228 |  |  | $ | 2,447,160 |
PrepaCyte CB |  |  | (61,002 | ) |  |  | (2,013,566 | )
Total operating profit |  | $ | 5,006,226 |  |  | $ | 433,594 |
Depreciation and amortization: |  |  |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 193,741 |  |  | $ | 240,916 |
PrepaCyte CB |  |  | 36,254 |  |  |  | 45,734 |
Total depreciation and amortization |  | $ | 229,995 |  |  | $ | 286,650 |
Interest expense: |  |  |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 1,302,650 |  |  | $ | 925,075 |
PrepaCyte CB |  |  | — |  |  |  | 22,265 |
Total interest expense |  | $ | 1,302,650 |  |  | $ | 947,340 |
Income tax (expense) benefit: |  |  |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | (1,308,603 | ) |  | $ | 1,141,823 |
PrepaCyte CB |  |  | — |  |  |  | 17,589 |
Total income tax (expense) benefit |  | $ | (1,308,603 | ) |  | $ | 1,159,412 |
Other comprehensive income (loss): |  |  |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 6,457 |  |  | $ | (135,524 | )
PrepaCyte CB |  |  | — |  |  |  | — |
Total other comprehensive income (loss) |  | $ | 6,457 |  |  | $ | (135,524 | )
The following table shows the assets by segment as of November 30 2017 and November 30, 2016:
Assets: |  |  |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 23,360,714 |  |  | $ | 18,960,261 |
PrepaCyte CB |  |  | 549,283 |  |  |  | 578,207 |
Total assets |  | $ | 23,909,997 |  |  | $ | 19,538,468 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration